DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Malignant Pleural Effusion
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: carboplatin
Drug: bortezomib
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT00052338

Locations: 🇺🇸
City of Hope, Duarte, California, United States

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: gemcitabine hydrochloride
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00039403

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Phase 3

Completed

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: shark cartilage extract AE-941
Other: placebo
Drug: cisplatin
Drug: vinorelbine tartrate
Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 756

Registration Number: NCT00005838

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

Phase 2

Terminated

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer

Interventions: Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00047333

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00045188

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Childhood Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT00030394

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma

Phase 2

Completed

Conditions: Alveolar Childhood Rhabdomyosarcoma
Embryonal Childhood Rhabdomyosarcoma
Embryonal-botryoid Childhood Rhabdomyosarcoma
Previously Treated Childhood Rhabdomyosarcoma
Recurrent Childhood Rhabdomyosarcoma

Interventions: Drug: vincristine sulfate
Drug: irinotecan hydrochloride
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: etoposide
Drug: tirapazamine
Biological: filgrastim
Biological: sargramostim
Other: pharmacological study
Other: pharmacogenomic studies
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 150

Registration Number: NCT00025363

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Phase 1

Terminated

Conditions: AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Primary CNS Lymphoma
Post-transplant Lymphoproliferative Disorder
Recurrent Childhood Large Cell Lymphoma
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Childhood Small Noncleaved Cell Lymphoma
Recurrent/Refractory Childhood Hodgkin Lymphoma

Interventions: Biological: rituximab
Radiation: indium In 111 ibritumomab tiuxetan
Radiation: yttrium Y 90 ibritumomab tiuxetan
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis
Biological: filgrastim

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00036855

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Phase 2

Completed

Conditions: Cervical Squamous Cell Carcinoma
Recurrent Cervical Cancer

Interventions: Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00031993

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Cardiac Toxicity
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: oblimersen sodium
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: filgrastim
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00039481

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy